OncoSec Medical Stock Forecast, Price & News

+0.05 (+2.34 %)
(As of 08/5/2021 12:05 PM ET)
Today's Range
50-Day Range
52-Week Range
Volume1,101 shs
Average Volume4.95 million shs
Market Capitalization$85.83 million
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive ONCS News and Ratings via Email

Sign-up to receive the latest news and ratings for OncoSec Medical and its competitors with MarketBeat's FREE daily newsletter.

OncoSec Medical logo

About OncoSec Medical

OncoSec Medical Incorporated, a biotechnology company, focuses on developing cytokine-based intratumoral immunotherapies to stimulate the body's immune system to target and attack cancer. The company's lead product candidate is ImmunoPulse IL-12 that uses electroporation device to deliver a DNA-encoded interleukin-12 (IL-12) for reversing the immunosuppressive microenvironment in the treated tumor. It is also developing ImmunoPulse IL-12 with KEYTRUDA in patients with advanced melanoma that is in Phase IIb clinical trials (KEYNOTE-695) and advanced or metastatic triple negative breast cancer (TNBC), which is in Phase II clinical trials (KEYNOTE-890); ImmunoPulse IL-12 and KEYTRUDA in patients with advanced or metastatic melanoma that has completed Phase II clinical trials; and ImmunoPulse IL-12 monotherapy in patients with metastatic melanoma, which has completed the Phase II clinical trials. In addition, the company is developing monotherapy biomarker study in patients with advanced or metastatic TNBC that has completed the Phase II clinical trials; and new DNA-encoded therapeutic candidates and tumor indications to treat deep visceral lesions, such as liver, lung, bladder, pancreatic, and other visceral lesions. It has clinical trial collaborations with Merck & Co., Inc. and its subsidiary in connection with the KEYNOTE-695 and KEYNOTE-890 studies; a research collaboration with Duke University's Center for Applied Therapeutics to evaluate enhanced IL-12 DNA-plasmid; a research collaboration with Roswell Park Comprehensive Cancer Center to evaluate the use of Roswell Park's intravital microscopy and enhanced IL-12 DNA-plasmid; and collaboration with Providence Cancer Institute. The company was formerly known as NetVentory Solutions Inc. and changed its name to OncoSec Medical Incorporated in March 2011. OncoSec Medical Incorporated was founded in 2008 and is headquartered in Pennington, New Jersey.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

1.79 out of 5 stars

Medical Sector

764th out of 1,311 stocks

Pharmaceutical Preparations Industry

380th out of 647 stocks

Analyst Opinion: 3.5Community Rank: 4.0Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

OncoSec Medical (NASDAQ:ONCS) Frequently Asked Questions

Is OncoSec Medical a buy right now?

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for OncoSec Medical in the last year. There are currently 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" OncoSec Medical stock.
View analyst ratings for OncoSec Medical
or view top-rated stocks.

What stocks does MarketBeat like better than OncoSec Medical?

Wall Street analysts have given OncoSec Medical a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but OncoSec Medical wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting OncoSec Medical?

OncoSec Medical saw a increase in short interest in the month of July. As of July 15th, there was short interest totaling 1,030,000 shares, an increase of 205.6% from the June 30th total of 337,000 shares. Based on an average trading volume of 1,630,000 shares, the short-interest ratio is currently 0.6 days. Approximately 6.1% of the shares of the company are short sold.
View OncoSec Medical's Short Interest

When is OncoSec Medical's next earnings date?

OncoSec Medical is scheduled to release its next quarterly earnings announcement on Wednesday, October 27th 2021.
View our earnings forecast for OncoSec Medical

How were OncoSec Medical's earnings last quarter?

OncoSec Medical Incorporated (NASDAQ:ONCS) issued its quarterly earnings results on Friday, June, 11th. The biotechnology company reported ($0.25) earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($0.26) by $0.01.
View OncoSec Medical's earnings history

How has OncoSec Medical's stock price been impacted by Coronavirus?

OncoSec Medical's stock was trading at $1.37 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, ONCS shares have increased by 54.7% and is now trading at $2.12.
View which stocks have been most impacted by COVID-19

When did OncoSec Medical's stock split? How did OncoSec Medical's stock split work?

Shares of OncoSec Medical reverse split on the morning of Tuesday, May 21st 2019. The 1-10 reverse split was announced on Monday, May 20th 2019. The number of shares owned by shareholders was adjusted after the closing bell on Monday, May 20th 2019. An investor that had 100 shares of OncoSec Medical stock prior to the reverse split would have 10 shares after the split.

What price target have analysts set for ONCS?

5 analysts have issued 12-month price objectives for OncoSec Medical's stock. Their forecasts range from $8.00 to $12.00. On average, they anticipate OncoSec Medical's stock price to reach $10.25 in the next twelve months. This suggests a possible upside of 383.5% from the stock's current price.
View analysts' price targets for OncoSec Medical
or view top-rated stocks among Wall Street analysts.

Who are OncoSec Medical's key executives?

OncoSec Medical's management team includes the following people:
  • Mr. Robert J. DelAversano CPA, VP of Fin. and Principal Accounting Officer & Controller (Age 49, Pay $503.03k)
  • Mr. Brian A. Leuthner, Interim CEO & COO (Age 56)
  • Dr. Kim Jaffe, Assistant VP of Bus. Devel. & Operations
  • Dr. Christopher G. Twitty Ph.D., Chief Scientific Officer (Age 48)
  • Mr. Tu Diep, Sr. VP & Head of Operations
  • Dr. Robert W. Ashworth, Sr. VP of Regulatory, Quality & CMC
  • Dr. Sandra Aung Ph.D., Sr. VP & Chief Clinical Devel. Officer
  • Dr. Mai Hope Le M.D., Consultant (Age 45)

What is Punit Dhillon's approval rating as OncoSec Medical's CEO?

2 employees have rated OncoSec Medical CEO Punit Dhillon on Punit Dhillon has an approval rating of 50% among OncoSec Medical's employees. This puts Punit Dhillon in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of OncoSec Medical's key competitors?

What other stocks do shareholders of OncoSec Medical own?

Based on aggregate information from My MarketBeat watchlists, some companies that other OncoSec Medical investors own include Cytokinetics (CYTK), Inovio Pharmaceuticals (INO), XOMA (XOMA), Anavex Life Sciences (AVXL), The Walt Disney (DIS), Idera Pharmaceuticals (IDRA), Sorrento Therapeutics (SRNE), Amarin (AMRN), Dynavax Technologies (DVAX) and Trevena (TRVN).

What is OncoSec Medical's stock symbol?

OncoSec Medical trades on the NASDAQ under the ticker symbol "ONCS."

Who are OncoSec Medical's major shareholders?

OncoSec Medical's stock is owned by many different institutional and retail investors. Top institutional shareholders include GSA Capital Partners LLP (0.08%) and Envestnet Asset Management Inc. (0.03%). Company insiders that own OncoSec Medical stock include Alpha Holdings, Inc, Brian A Leuthner, Daniel J O'connor, Grand Pharmaceutical & H China, Robert J Delaversano and Sara Bonstein.
View institutional ownership trends for OncoSec Medical

Which major investors are buying OncoSec Medical stock?

ONCS stock was acquired by a variety of institutional investors in the last quarter, including GSA Capital Partners LLP, and Envestnet Asset Management Inc..
View insider buying and selling activity for OncoSec Medical
or or view top insider-buying stocks.

How do I buy shares of OncoSec Medical?

Shares of ONCS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is OncoSec Medical's stock price today?

One share of ONCS stock can currently be purchased for approximately $2.12.

How much money does OncoSec Medical make?

OncoSec Medical has a market capitalization of $83.08 million. The biotechnology company earns $-42,250,000.00 in net income (profit) each year or ($2.56) on an earnings per share basis.

How many employees does OncoSec Medical have?

OncoSec Medical employs 42 workers across the globe.

What is OncoSec Medical's official website?

The official website for OncoSec Medical is

Where are OncoSec Medical's headquarters?

OncoSec Medical is headquartered at 3565 GENERAL ATOMICS COURT, SAN DIEGO CA, 92121.

How can I contact OncoSec Medical?

OncoSec Medical's mailing address is 3565 GENERAL ATOMICS COURT, SAN DIEGO CA, 92121. The biotechnology company can be reached via phone at 855-662-6732 or via email at [email protected]

This page was last updated on 8/5/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.